162 related articles for article (PubMed ID: 28121908)
1. Characterizing the Risk of False-Positive Hepatocellular Carcinoma in Recipients Transplanted With T2 MELD Exceptions.
Bittermann T; Goldberg DS; Bauer CM; Khungar V
Transplantation; 2017 May; 101(5):1099-1105. PubMed ID: 28121908
[TBL] [Abstract][Full Text] [Related]
2. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
[TBL] [Abstract][Full Text] [Related]
3. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
[TBL] [Abstract][Full Text] [Related]
4. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form.
Mehta N; Dodge JL; Roberts JP; Hirose R; Yao FY
Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28881064
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
Berry K; Ioannou GN
Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
[TBL] [Abstract][Full Text] [Related]
6. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
[TBL] [Abstract][Full Text] [Related]
7. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
[TBL] [Abstract][Full Text] [Related]
8. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.
Ioannou GN; Perkins JD; Carithers RL
Gastroenterology; 2008 May; 134(5):1342-51. PubMed ID: 18471511
[TBL] [Abstract][Full Text] [Related]
9. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list.
Toso C; Majno P; Berney T; Morel P; Mentha G; Combescure C
Transpl Int; 2014 Jul; 27(7):686-95. PubMed ID: 24649861
[TBL] [Abstract][Full Text] [Related]
10. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
[TBL] [Abstract][Full Text] [Related]
11. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
[TBL] [Abstract][Full Text] [Related]
12. Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.
Bhat M; Ghali P; Dupont B; Hilzenrat R; Tazari M; Roy A; Chaudhury P; Alvarez F; Carrier M; Bilodeau M
J Hepatol; 2017 Feb; 66(2):374-381. PubMed ID: 27751840
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes in liver transplant recipients with hepatocellular carcinoma.
Kensinger CD; Feurer ID; O'Dell HW; LaNeve DC; Simmons L; Pinson CW; Moore DE
Clin Transplant; 2016 Sep; 30(9):1036-45. PubMed ID: 27291713
[TBL] [Abstract][Full Text] [Related]
14. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
Goldberg D; French B; Abt P; Feng S; Cameron AM
Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
[TBL] [Abstract][Full Text] [Related]
15. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing.
Mehta N; Sarkar M; Dodge JL; Fidelman N; Roberts JP; Yao FY
Liver Transpl; 2016 Feb; 22(2):178-87. PubMed ID: 26479422
[TBL] [Abstract][Full Text] [Related]
16. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD.
Hayashi PH; Trotter JF; Forman L; Kugelmas M; Steinberg T; Russ P; Wachs M; Bak T; Kam I; Everson GT
Liver Transpl; 2004 Jan; 10(1):42-8. PubMed ID: 14755776
[TBL] [Abstract][Full Text] [Related]
17. The race to liver transplantation: a comparison of patients with and without hepatocellular carcinoma from listing to post-transplantation.
Patel MS; Kohn R; Kratz JR; Shah JA; Markmann JF; Vagefi PA
J Am Coll Surg; 2015 Jun; 220(6):1001-7. PubMed ID: 25868408
[TBL] [Abstract][Full Text] [Related]
18. Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry.
Taniguchi M
Clin Transpl; 2012; ():41-65. PubMed ID: 23721009
[TBL] [Abstract][Full Text] [Related]
19. HCC patients suffer less from geographic differences in organ availability.
Schuetz C; Dong N; Smoot E; Elias N; Schoenfeld DA; Markmann JF; Yeh H
Am J Transplant; 2013 Nov; 13(11):2989-95. PubMed ID: 24011291
[TBL] [Abstract][Full Text] [Related]
20. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
